BJ
BJX1.F BioLife Solutions Inc
- Market cap
- EUR 1.60B
- P/E
- 38.6x
- P/B
- 4.30x
- ROE
- 22.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BJX1.F undervalued?
Graham numberBJX1.F trades 171.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioLife Solutions Inc fundamental analysis
No fundamental analysis for BioLife Solutions Inc yet.
BioLife Solutions Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitiga…
Full company profileBioLife Solutions Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioLife Solutions Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.23M | 11.0M | 19.7M | 27.4M | 48.1M | 119M | 162M | 68.0M | 74.6M | 96.2M | 112M |
| Gross Profit | 4.78M | 6.75M | 13.5M | 18.6M | 27.4M | 37.7M | 53.8M | 41.3M | 50.1M | 62.1M | 71.6M |
| Operating Income | -4.85M | -1.06M | 3.66M | 770K | -3.33M | -30.4M | -39.9M | -19.4M | -4.48M | -16.6M | 3.45M |
| EBITDA | - | -1.99M | 3.61M | -1.40M | 1.74M | -22.2M | -134M | -7.10M | 4.18M | -11.9M | 6.46M |
| Net Income | -6.88M | -2.52M | 3.27M | -1.66M | 2.67M | -8.38M | -140M | -68.0M | -20.2M | -4.60M | 92.6M |
| EPS | - | -0.18 | 0.18 | -0.08 | 0.08 | -0.20 | -3.26 | -1.51 | -0.43 | -0.10 | 1.89 |
| Balance Sheet | |||||||||||
| Total Assets | 7.93M | 12.1M | 45.5M | 92.8M | 235M | 553M | 450M | 413M | 399M | 406M | 447M |
| Total Liabilities | 4.76M | 2.05M | 2.32M | 49.4M | 29.6M | 71.9M | 86.0M | 75.1M | 50.6M | 34.0M | 27.5M |
| Shareholders' Equity | 3.17M | 10.1M | 43.1M | 43.5M | 205M | 481M | -247M | 338M | 349M | 372M | 420M |
| Cash & Short-term Investments | 1.41M | 6.66M | 30.7M | 6.45M | 90.5M | 69.9M | 19.4M | 35.4M | 95.4M | 33.0M | 24.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.33M | 605K | 2.35M | 1.21M | 6.65M | -4.59M | -8.49M | -12.5M | 8.43M | 20.1M | 11.7M |
| Capital Expenditure | 1.26M | 144K | 500K | 2.33M | 7.81M | 14.8M | 10.4M | 6.38M | 3.53M | 19.7M | 2.66M |
| Free Cash Flow | - | 461K | 1.85M | 538K | 2.01M | -4.84M | -8.49M | -18.9M | 4.90M | 416K | 9.05M |
| Ratios | |||||||||||
| ROE | -217.2% | -24.9% | 7.6% | -3.8% | 1.3% | -1.7% | - | -20.1% | -5.8% | -1.2% | 22.0% |
| ROA | -86.7% | -20.7% | 7.2% | -1.8% | 1.1% | -1.5% | -31.1% | -16.5% | -5.1% | -1.1% | 20.7% |
| Net Profit Margin | -83.6% | -22.8% | 16.5% | -6.1% | 5.5% | -7.0% | -86.4% | -100.0% | -27.0% | -4.8% | 82.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioLife Solutions Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 436K | 0.02 | 13.3% |
| 2017 | USD 106K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioLife Solutions Inc
- Insiders 2.61%
- Institutions 97.39%
- Public & others 0.00%
- Shares outstanding 48.9M
- Free float 40.1M
BioLife Solutions Inc company profile
- Company name
- BioLife Solutions Inc
- Ticker
- BJX1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 155
- Fiscal year end
- December
- Address
- 3303 Monte Villa Parkway, Bothell, WA, United States, 98021
- Phone
- 425 402 1400
- Website
- biolifesolutions.com
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions Inc management
5- Mr. Roderick de GreefCEO & Chairman · born 1960
- Mr. Troy Wichterman CPAChief Financial Officer · born 1985
- Mr. Sean Werner Ph.D.Chief Technology Officer · born 1974
- Dr. Aby J. Mathew Ph.D.Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer · born 1972
- Mr. Todd BerardChief Commercial Officer · born 1969